Sunday 11 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Legal Wrangle Over RU-486 In USA

Legal Wrangle Over RU-486 In USA

25 November 1996

NeoGen Investors has filed a defamation suit against Hollywood, USA industrialist Burt Sugarman and his Giant Group, claiming they have slandered and defamed Joseph Pike, NeoGen's founder, to try to force him to give up the rights to the abortion pill mifepristone (also known as RU-486). Mr Pike holds US manufacturing and distribution rights to the product.

Giant further says it invested $6 million in the marketing effort. Last month, Giant Group subsidiary KCC Delaware sued Mr Pike and accused him of hiding his criminal past when he was negotiating the $6 million deal. NeoGen claims that the KCC suit has left Mr Pike and his family open to threats from antiabortion groups; its suit further states that Giant did not pay any money and that an exclusive agreement with NeoGen expired at the end of September. A Giant spokesman said that the money was not due until mifepristone was approved by the US Food and Drug Administration.

The nonprofit Population Council, to which mifepristone's developer Roussel Uclaf transferred US patent rights, has subleased its rights to several companies, including NeoGen. The Council, saying it would not have given NeoGen rights had it known that Mr Pike was disbarred in North Carolina in 1993 for forgery and fraud in a real estate deal, has asked for a court order to force Mr Pike to give up control of companies that make the pill in the USA. The Council says that this abortifacient has a possible $100 million market in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

The week in pharma: action, reaction and insight – week to May 9
Biotechnology
The week in pharma: action, reaction and insight – week to May 9
11 May 2025
Biotechnology
IGM Biosciences says it is dropping development of imvotamab
10 May 2025
Biotechnology
Boundless Bio reports R&D pipeline progress
10 May 2025
Pharmaceutical
M&A activity – Radiopharmaceutical therapies are a hot target for investment
9 May 2025
Pharmaceutical
Thin on detail, UK-US trade agreement is a first step, says ABPI
9 May 2025
Pharmaceutical
Oculis posts widening quarterly loss as R&D spend climbs
9 May 2025
Pharmaceutical
HIV market to surpass $32 billion across 7MM in 2033
9 May 2025

Company Spotlight

A T-cell immunotherapy company leveraging its novel allogeneic EBV T-cell platform to develop therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze